The InterVenn Investigator-Initiated Research (I3R) Program supports translational and clinical oncology researchers in exploring the power of high-throughput glycoproteomics to discover novel biomarkers for advances in patient care.
InterVenn, the leader in the application of glycoproteomics for biomarker discovery, is requesting proposals that address clinical oncology challenges where the discovery and application of liquid-biopsy-based biomarkers will advance disease diagnosis, prognostication, or management, such as therapy response prediction and monitoring.
Investigator Requirements of the I3R Program
Researchers are invited to submit their proposal through the I3R portal. Submission will be reviewed collectively by the InterVenn Review Committee based on scientific merit and alignment with corporate research and development plans.
We thank you for your interest and look forward to reviewing your proposal.
Klaus Lindpaintner, M.D., MPH
Chief Scientific and Medical Officer